http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014017223-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14b3acfd17ee0ac1f79ad009b144c204
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32263
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14363
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-54
filingDate 2013-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1b3d20f334eccb9c690a9996b5e8380
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b488180ee464401370bd03e9e06f8a0
publicationDate 2014-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2014017223-A1
titleOfInvention Pharmaceutical Compositions Comprising A Pancreatic Enzyme Preparation With Viral Infectivity Reduced Below A Significant Level And Methods Of Preparing And Using The Same
abstract The present invention provides for pharmaceutical compositions comprising pancreatic enzyme preparations (PEPs) with viral infectivity reduced below significant levels and having high enzymatic activity. The PEPs can comprise lipases, proteases, amylases, non-enveloped viruses (e.g., porcine parvovirus (PPV), porcine circovirus type 2 (PCV-2), porcine encephalomyocarditis virus (EMCV)), and enveloped viruses (e.g., vesicular stomatitis virus (VSV), and influenza A (IFA)). The present invention also includes methods of treating pancreatic insufficiency by administering these pharmaceutical compositions and methods of making the same by treating the PEP with beta-propiolactone (BPL) to reduce viral infectivity.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10093916-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10471090-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016187455-A1
priorityDate 2010-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68152
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396167
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127424782
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394044
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID517055
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129465587
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54676860
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5585

Total number of triples: 46.